Intellia Therapeutics (NASDAQ:NTLA) Now Covered by Credit Suisse Group

Credit Suisse Group initiated coverage on shares of Intellia Therapeutics (NASDAQ:NTLAGet Rating) in a report issued on Thursday, The Fly reports. The brokerage set an “outperform” rating and a $100.00 price target on the stock. Credit Suisse Group’s price objective would suggest a potential upside of 102.68% from the stock’s current price.

NTLA has been the topic of a number of other research reports. Cowen began coverage on Intellia Therapeutics in a research report on Monday, January 31st. They set an “outperform” rating on the stock. Brookline Capital Acquisition raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 target price on the stock in a research report on Monday, March 7th. Robert W. Baird decreased their price target on Intellia Therapeutics from $146.00 to $83.00 in a research note on Tuesday, March 1st. JMP Securities reiterated a “buy” rating and set a $165.00 target price on shares of Intellia Therapeutics in a research note on Monday, March 21st. Finally, Brookline Capital Management upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a research note on Monday, March 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $147.25.

Intellia Therapeutics stock opened at $49.34 on Thursday. Intellia Therapeutics has a 12-month low of $48.07 and a 12-month high of $202.73. The business’s 50-day simple moving average is $68.69 and its 200 day simple moving average is $98.16. The stock has a market cap of $3.68 billion, a price-to-earnings ratio of -13.12 and a beta of 2.01.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last released its earnings results on Thursday, February 24th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.18). Intellia Therapeutics had a negative net margin of 810.49% and a negative return on equity of 33.61%. The company had revenue of $12.90 million during the quarter, compared to analyst estimates of $7.83 million. During the same period in the previous year, the company posted ($0.69) EPS. The company’s quarterly revenue was up 95.5% compared to the same quarter last year. Research analysts predict that Intellia Therapeutics will post -4.36 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of NTLA. Amalgamated Bank lifted its holdings in Intellia Therapeutics by 1.5% during the third quarter. Amalgamated Bank now owns 12,245 shares of the company’s stock worth $1,643,000 after acquiring an additional 182 shares during the period. SG Americas Securities LLC increased its position in Intellia Therapeutics by 44.0% in the third quarter. SG Americas Securities LLC now owns 14,527 shares of the company’s stock worth $1,949,000 after buying an additional 4,440 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Intellia Therapeutics by 11.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 10,994 shares of the company’s stock worth $1,475,000 after buying an additional 1,164 shares during the last quarter. Raymond James & Associates grew its position in shares of Intellia Therapeutics by 14.6% in the third quarter. Raymond James & Associates now owns 28,186 shares of the company’s stock valued at $3,781,000 after purchasing an additional 3,592 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its position in shares of Intellia Therapeutics by 1.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 35,009 shares of the company’s stock valued at $4,696,000 after purchasing an additional 373 shares in the last quarter. Institutional investors and hedge funds own 86.60% of the company’s stock.

Intellia Therapeutics Company Profile (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Recommended Stories

The Fly logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.